2021
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNAFLD fibrosis scoreCardiorenal outcomesFibrosis riskEMPA-REG OUTCOMELiver fat contentRisk of steatosisEffect of empagliflozinFatty liver diseaseType 2 diabetesCause deathDaily empagliflozinSteatosis indexHeart failureFibrosis scoreLiver diseaseCox regressionCardiovascular diseaseHigh riskEmpagliflozinPlaceboSteatosisRisk categoriesBaselineMeasures analysisEmpagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial
Inzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.Peer-Reviewed Original ResearchCardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME
Kraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME. Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.Peer-Reviewed Original ResearchEmpagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
Fitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.Peer-Reviewed Original ResearchEffect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial
Hamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial. Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.Peer-Reviewed Original Research
2020
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin
2019
Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c
Wanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c. Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.Peer-Reviewed Original Research
2018
EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE
Fitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE. Canadian Journal Of Cardiology 2018, 34: s80-s81. DOI: 10.1016/j.cjca.2018.07.288.Peer-Reviewed Original ResearchP5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. European Heart Journal 2018, 39: ehy566.p5334. DOI: 10.1093/eurheartj/ehy566.p5334.Peer-Reviewed Original Research
2017
CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
Inzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME. Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.Peer-Reviewed Original Research
2016
10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk. Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.Peer-Reviewed Original ResearchEFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL
Fitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.Peer-Reviewed Original ResearchEFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.Peer-Reviewed Original Research